Company Overview and News

0
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 theage.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.
VOC VCMMF MTCZF MTU MGRPY

0
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 smh.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.
VOC VCMMF MTCZF MTU MGRPY

0
Former Optus boss to lead Vocus

2018-05-21 businessnews.com.au
Vocus Communications has appointed former Optus boss Kevin Russell as managing director and chief executive, three months after Geoff Horth quit the broadband provider in the wake of an earnings warning.
VOC VCMMF

5
Spark sells 50 pct stake in services infrastructure unit to Electra Group

2018-05-03 nzherald.co.nz
Spark New Zealand is selling half of its Connect 8 services infrastructure unit to electricity distributor Electra Group, in a deal which will see Connect 8 take full ownership of Electra's telecommunication's contractor Sky Communications.
VOC VCMMF NZTCY SPKKY SPK NZTCF

0
Committee recommends against easing restrictions on Chorus' business

2018-05-03 nzherald.co.nz
Removing restrictions on the services provided by Chorus would risk distorting competition in the telecommunications market, a parliamentary committee says.
VOC VCMMF

0
Spark warns of broadband price increases under proposed changes to telecommunications regulations

2018-04-24 nzherald.co.nz
Broadband prices could increase by up to $8 a month for every household and business in the country if a bill updating the telecommunications industry is passed unchanged, Spark has warned.
VOC VCMMF

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...